Trial Profile
An Open-Label, Crossover, Dose-Escalation, and Multi-Center Study to Determine the Safety, Tolerability, and Pharmacokinetic of a Single Intravenous Injection of rFVIIIFc in Previously Treated Patients With Severe Hemophilia A
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Efmoroctocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Sponsors Biogen Idec
- 14 Mar 2021 Results of population pharmacokinetic model from NCT01027377, NCT01181128 and NCT01458106 published in the Journal of Clinical Pharmacology
- 08 Dec 2014 New trial record